These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 17634492)

  • 21. [Treatment of advanced Wilms' tumor].
    Li MJ; Huang Y; Tang DX; Zhou YB; Tang HF; Liang JF
    Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):791-5. PubMed ID: 17366799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients.
    Denschlag D; Watermann D; Hörig K; Kissel C; Tempfer C; Gitsch G
    Anticancer Res; 2004; 24(2C):1267-9. PubMed ID: 15154658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group.
    Bernstein ML; Devidas M; Lafreniere D; Souid AK; Meyers PA; Gebhardt M; Stine K; Nicholas R; Perlman EJ; Dubowy R; Wainer IW; Dickman PS; Link MP; Goorin A; Grier HE; ; ;
    J Clin Oncol; 2006 Jan; 24(1):152-9. PubMed ID: 16382125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Late recurrence in children with Wilms' tumor.
    Büyükpamukçu M; Köksal Y; Varan A; Atahan L; Cağlar M; Akyüz C; Kutluk T; Büyükpamukçu N
    Turk J Pediatr; 2007; 49(2):226-30. PubMed ID: 17907529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relapse of unilateral favorable histology Wilms' tumor: significant clinicopathological factors.
    Aoba T; Urushihara N; Fukumoto K; Furuta S; Fukuzawa H; Mitsunaga M; Watanabe K; Yamoto M; Miyake H; Koyama M; Iwabuchi H; Koike J; Tatsunami S; Wakisaka M; Kitagawa H
    J Pediatr Surg; 2012 Dec; 47(12):2210-5. PubMed ID: 23217878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment outcomes in adults with favorable histologic type Wilms tumor-an update from the National Wilms Tumor Study Group.
    Kalapurakal JA; Nan B; Norkool P; Coppes M; Perlman E; Beckwith B; Ritchey M; Breslow N; Grundy P; D'angio GJ; Green DM; Thomas PR
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1379-84. PubMed ID: 15590168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
    Boss DS; Siegel-Lakhai WS; van Egmond-Schoemaker NE; Pluim D; Rosing H; Ten Bokkel Huinink WW; Beijnen JH; Schellens JH
    Clin Cancer Res; 2009 Jul; 15(13):4475-83. PubMed ID: 19531625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of relapsed Wilms tumour (WT) patients: experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG).
    Mavinkurve-Groothuis AM; van den Heuvel-Eibrink MM; Tytgat GA; van Tinteren H; Vujanic G; Pritchard-Jones KL; Howell L; Graf N; Bergeron C; Acha T; Catania S; Spreafico F
    Pediatr Blood Cancer; 2015 Apr; 62(4):598-602. PubMed ID: 25546733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study.
    Koensgen D; Stengel D; Belau A; Klare P; Oskay-Oezcelik G; Steck T; Camara O; Mustea A; Sommer H; Coumbos A; Bogenrieder T; Lichtenegger W; Sehouli J;
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):393-400. PubMed ID: 17922272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic significance of blastemal predominant histology in initially resected Wilms' tumors: a report from the Study Group for Pediatric Solid Tumors in the Kyushu Area, Japan.
    Kinoshita Y; Suminoe A; Inada H; Yagi M; Yanai F; Zaizen Y; Nishi M; Inomata Y; Kawakami K; Matsufuji H; Suenobu S; Handa N; Kohashi K; Oda Y; Hara T; Taguchi T
    J Pediatr Surg; 2012 Dec; 47(12):2205-9. PubMed ID: 23217877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
    J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wilms' tumor in adults: results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) Study.
    Reinhard H; Aliani S; Ruebe C; Stöckle M; Leuschner I; Graf N
    J Clin Oncol; 2004 Nov; 22(22):4500-6. PubMed ID: 15542800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Herzog TJ; Powell MA; Rader JS; Gibb RK; Lippmann L; Coleman RL; Mutch DG
    Gynecol Oncol; 2008 Dec; 111(3):467-73. PubMed ID: 18834619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.
    Malogolowkin M; Cotton CA; Green DM; Breslow NE; Perlman E; Miser J; Ritchey ML; Thomas PR; Grundy PE; D'Angio GJ; Beckwith JB; Shamberger RC; Haase GM; Donaldson M; Weetman R; Coppes MJ; Shearer P; Coccia P; Kletzel M; Macklis R; Tomlinson G; Huff V; Newbury R; Weeks D;
    Pediatr Blood Cancer; 2008 Feb; 50(2):236-41. PubMed ID: 17539021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93.
    Wadler S; Levy DE; Lincoln ST; Soori GS; Schink JC; Goldberg G
    J Clin Oncol; 2003 Jun; 21(11):2110-4. PubMed ID: 12775736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bilateral Wilms' tumor with anaplasia: lessons from the National Wilms' Tumor Study.
    Hamilton TE; Green DM; Perlman EJ; Argani P; Grundy P; Ritchey ML; Shamberger RC
    J Pediatr Surg; 2006 Oct; 41(10):1641-4. PubMed ID: 17011261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Der(16)t(1;16)(q21;q13) in Wilms' tumor: friend or foe.
    Mathew P; Douglass EC; Jones D; Valentine M; Valentine V; Rowe S; Shapiro DN
    Med Pediatr Oncol; 1996 Jul; 27(1):3-7. PubMed ID: 8614388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy for recurrent cervical cancer.
    Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
    Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic relevance of preoperative transcatheter arterial chemoembolization (TACE) and PCNA/VEGF expression in patients with Wilms' tumour.
    Liu WG; Gu WZ; Zhou YB; Tang HF; Li MJ; Ma WX
    Eur J Clin Invest; 2008 Dec; 38(12):931-8. PubMed ID: 19021718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.